Výsledky vyhledávání - "Matthew James Butler"

Oxidatively modified low‐density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma

Autor: Srikanth R. Polusani, Hongxin Fan, Marsha C. Kinney, Javier Esparza, Huynh Nga Nguyen, Matthew James Butler, Samy L. Habib, Gopalrao V.N. Velagaleti, Edward A. Medina, Valerie Cortez, Babatunde O. Oyajobi, Reto Asmis

Publikováno v: Int J Cancer

Proteasome inhibitor (PI) therapy has improved the survival of multiple myeloma (MM) patients. However, inevitably, primary or acquired resistance to PIs leads to disease progression; resistance mechanisms are unclear. Obesity is a risk factor for MM

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f53e23da4185a56de9c00590c5b75fa
https://doi.org/10.1002/ijc.33497

Zobrazit plný text záznamu

60 Development and validation of blood tumor mutational burden reference standards

Autor: Eun-Ang Rabier-Moreau, James Hadfield, Guillem Portella, Matthew James Butler, Yves Konigshofer

Publikováno v: Regular and young investigator award abstracts.

Background Tumor mutational burden (TMB), as measured by exome or panel sequencing of tumor tissue (tTMB) or blood (bTMB), has been identified as a potential predictive biomarker for treatment benefit in patients with various cancer types receiving i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8488659436a6c102f3a76defc2218884
https://doi.org/10.1136/jitc-2020-sitc2020.0060

Zobrazit plný text záznamu

Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma

Autor: Ricardo C.T. Aguiar, Matthew James Butler

Publikováno v: Trends in Cancer. 3:871-882

The effective deployment of rationally developed therapies for diffuse large B cell lymphoma (DLBCL) requires rapid assimilation of new biological data. Within this framework, here we address topical issues at the intersection of DLBCL biology and th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::758fdb3e4ab66e5c5baa4c9a6f861b7b
https://doi.org/10.1016/j.trecan.2017.09.008

Zobrazit plný text záznamu

Echocardiography-Defined Pulmonary Hypertension in Multiple Myeloma: Risk Factors and Impact on Outcomes

Autor: Andrea Berger, H Lester Kirchner, Rahul Sangani, Matthew James Butler, Jason Stamm

Publikováno v: Southern Medical Journal. 109:282-289

Objectives Survival of patients with multiple myeloma (MM) has improved as a result of therapeutic advances. There is evidence that some patients with MM develop pulmonary hypertension (PH). The objective of this study was to identify risk factors of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::474dff394f0f19c4ae5993fd79b25ae0
https://doi.org/10.14423/smj.0000000000000461

Zobrazit plný text záznamu

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Autor: Ricardo C.T. Aguiar, Adolfo E Diaz, Anand B. Karnad, Matthew James Butler

Publikováno v: Blood. 134:1592-1592

R-CHOP remains the standard therapy for diffuse large B cell lymphoma (DLBCL), even though long-term disease free survival is achieved in only ~60-70% of the patients. One approach to improve on this cure rate is to implement rationally devised thera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9c82564167233f9ec462ed306dc7c97
https://doi.org/10.1182/blood-2019-124382

Zobrazit plný text záznamu

Tumor mutational burden reference materials for assay standardization

Autor: Matthew James Butler, Feras M. Hantash, Alexander F. Lovejoy, Li Liu, Keith M. Gligorich, Maria E. Arcila, Bharathi Anekella, Christian Gloeckner, Yves Konigshofer, Ravindra Kohle, Chen Zhao, Russell Garlick, Omoshile Clement, Carrie Sougnez, Ahmet Zehir, Niall J. Lennon, Anthony Martin Magliocco

Publikováno v: Journal of Clinical Oncology. 37:e14746-e14746

e14746 Background: Next Generation Sequencing based assays are designed to detect genomic aberrations in a limited number of target regions. However, there is a need for accurate measurement of tumor mutational burden (TMB) as low as 4 to as high as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::032ca5debfd840cf58fc086bfe1f2c13
https://doi.org/10.1200/jco.2019.37.15_suppl.e14746

Zobrazit plný text záznamu

TMB standardization by alignment to reference standards: Phase II of the Friends of Cancer Research TMB Harmonization Project

Autor: Shu-Jen Chen, Victor J Weigman, Chen Zhao, Arnaud Papin, Matthew James Butler, Laura E. MacConaill, Vincent Funari, David Fabrizio, Ahmet Zehir, Aparna Pallavajjala, Diana M. Merino, Jeffrey M. Conroy, Ruchi Chaudhary, Paul M. Williams, Wangjuh Sting Chen, Matthew D. Hellmann, Mark Sausen, Lisa M. McShane, Mingchao Xie

Publikováno v: Journal of Clinical Oncology. 37:2624-2624

2624 Background: Tumor mutational burden (TMB) is a predictive biomarker of response to immune checkpoint inhibitors across multiple cancers. In Phase 1 of the Friends of Cancer Research Harmonization Project, we demonstrated a robust correlation bet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b01401987d9b8a399966e1b72bdb15fc
https://doi.org/10.1200/jco.2019.37.15_suppl.2624

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání